Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma | Blood | American Society of Hematology ashpublications.org/blood/article/…

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology ASCO Journal of Clinical Oncology #mmsm ➡️ ascopubs.org/doi/pdf/10.120… Lisa Hicks Joseph Mikhael Hira Mian Rahul Banerjee, MD, FACP Ben Derman Shaji Kumar Susan Bal @MyelomaTeacher - Cindy Chmielewski

Leukemia highlights from #ASH25 w/ @GCC_Cortes: ✅ #PARADIGM ✅ Venetoclax dosing schedule ✅ #KOMET007 ✅ #ASC4First Full Discussion: ⭐️ oncbrothers.com/leukemia-ash25 ⭐️ Also on the “Oncology Brothers” podcast #HemeTwitter #MedTwitter OncUpdates

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

The Lancet Haematology doi.org/10.1016/S2352-… publica 8-2025 los resultados del ensayo fase 3 GEM-2017FIT del #GEMPETHEMA. Los esquemas KRd y D-KRd logran mayor negatividad de EMR que VMP–Rd en pacientes mayores con mieloma múltiple no candidatos a trasplante. #MielomaMúltiple

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma | Blood Cancer Journal nature.com/articles/s4140…

Infectious complications post Azacitidine + Venetoclax (Aza-Ven) 🦠💉 🧬 Why infections are common? 👉 Profound & prolonged neutropenia 👉 Functional immune suppression 👉 Older / unfit AML population 🔥 Most common infections 🦠 Bacterial (most frequent) Febrile neutropenia

Pola-Glo-Fi (Polatuzumab + Glofitamab) for Follicular Lymphoma 🔬🧬 🧠 What is Pola-Glo? ⚙️ Polatuzumab vedotin (anti-CD79b ADC) ➕ Glofitamab (CD20×CD3 bispecific T-cell engager) 🎯 Dual targeting: B-cell kill + T-cell activation 👤 Where used? 🔁 Relapsed / Refractory

Primary prophylaxis recommendations with Bispecifics and CAR-T s in myeloma by Meera Mohan at the 49th annual conference of MHG

Management of relapsed/refractory DLBCL in the era of novel agents and new approaches doi.org/10.1080/104281… #lymsm

Publicación PETHEMA en Cancer (01/01/2025) Estudio del Registro PETHEMA en HMA-sAML (n=479) confirma: Pronóstico muy desfavorable Beneficio del trasplante alogénico en 1ª RC Urgente necesidad de nuevos ensayos clínicos doi.org/10.1002/cncr.3… #PETHEMA #AML #Investigación

🧬 aCML (MDS/MPN with Neutropenia) – Practical Management Algorithm ( stepwise, exam + clinic oriented) 🔍 Step 1: Risk Stratification – “Who is high risk?” 🧠 Use clinical + molecular risk factors 🎂 Age ≥67 years → +1 🩸 Hb <10 g/dL → +1 🧪 TET2 mutation → +1 📊 Low

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL #lymsm doi.org/10.1016/j.blre…

Diagnosis & Management of Advanced Phase / Blast-Phase CML #CML #weekend_review #leusm

Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis - The Lancet Haematology thelancet.com/journals/lanha…

MDACC Algorithm for Ph+ ALL 🩸 🔹 Upfront: Ponatinib + Blinatumomab (+ HD MTX/Ara-C ×2 if WBC ≥70K) ➡️ MRD by NGS guides decisions • MRD− → Maintenance TKI • MRD+ → CAR-T →   – MRD− → Maintenance   – MRD+ → SCT Risk-adapted, MRD-driven strategy 👌 #POSS26

AML Therapeutic Timeline🧬 •1970–2000s: 7+3backbone ± •2017 :Targeted era begins  –FLT3(midostaurin, gilteritinib, quizartinib)  –IDH1/2(ivosidenib, enasidenib)  –CPX-351 for AML-MR  –Venetoclax + HMA/LDAC for unfit/older • 2024–2025: Menin inhibitors (revumenib, ziftomenib)

Targeted therapies in AML. So many! FLT3 mutation = gilteritinib, midostaurin, quizartinib IDH1 mutation = ivosidenib, olutasidenib IDH2 mutation = enasidenib KMT2A rearrangement = revumenib NPM1 mutatuion = revumenib, ziftomenib CD33 = gemtuzumab ozogamicin BCL2 = venetoclax

🆕🧬💉 Nueva evidencia en práctica clínica real sobre farmacogenética y cáncer de mama triple negativo metastásico Un estudio multicéntrico nacional promovido por la S.E.F.H analiza el impacto del polimorfismo #UGT1A1 en la seguridad y efectividad de un fármaco empleado en este

Do you know how to identify patients with acute myeloid leukemia who may have resistant disease after standard induction chemotherapy? The LSC17 score will help you. Don’t miss the news. haematologica.org/article/view/1…